ProCell Therapeutics, Inc.
PrivateLast Round
Series B
Jul 13, 2022
Est. Valuation
$24.56M
Total Funding Raised
$1.79M
Company Overview
ProCell Therapeutics, Inc. is a biotechnology company that develops recombinant protein-based therapeutics and drug delivery systems utilizing its proprietary macromolecule intracellular transduction technology (MITT) to treat incurable diseases and enhance cosmetic ingredient efficacy.
Sector
Healthcare & Life Sciences
Verticals
Biotechnology, Fashion & Beauty, Drug Discovery
Business Model
B2B
Customer Profile
Services & Consulting, Data as a Service, Hardware Sales
AI Layer
Non-AI
Keywords
Historical Pricing
Historical view of private secondary pricing and transaction trends.
ProCell Therapeutics, Inc. Comparables
Compare ProCell Therapeutics, Inc. with similar companies based on industry and business-model similarity.
| Company | Similarity | Market Cap |
|---|---|---|
| REMEDI Co., Ltd. | 77% | |
| Bio-FD&C Co. Ltd. | 68% | |
| Icure Pharmaceutical Inc. | 68% |
ProCell Therapeutics, Inc. Funding Rounds
Historical fundraising activity
| Round | Date | Amount Raised | Valuation | Investors | Sources |
|---|---|---|---|---|---|
| Series B | Jul 13, 2022 | ||||
| VC Round | Feb 1, 2010 | ||||
| VC Round | Jul 1, 2009 |
ProCell Therapeutics, Inc. Investors
Notable investors and investment history
| Investor | Rounds |
|---|---|
| Samsung Venture Investment | VC Round |
| Korea Credit Guarantee Fund | VC Round |
Market signals
Structured signals derived from secondary market and firmographic data.
- Jan 21, 2025
Monthly visitors increased 83% MoM.
- Oct 26, 2024
Monthly visitors increased 75% MoM to 2.1K.
ProCell Therapeutics, Inc. Filings
Explore SEC and related filing metadata, where available.
| Type | Date | Amount Offered | Amount Sold | Filing | Pages | Download |
|---|
Filing documents are not displayed on this public page. Request access to learn about available coverage.
Request accessFrequently Asked Questions
Common questions about ProCell Therapeutics, Inc.'s valuation, stock price, and market status.
Is ProCell Therapeutics, Inc. a public or private company?
ProCell Therapeutics, Inc. is a private company.
What is the current stock price of ProCell Therapeutics, Inc.?
ProCell Therapeutics, Inc. is a private company with no public stock price. No recent secondary market data is available.
How much is ProCell Therapeutics, Inc. worth (valuation)?
ProCell Therapeutics, Inc.'s valuation is estimated at $24.6M based on funding round data.
Can I buy ProCell Therapeutics, Inc. stock?
ProCell Therapeutics, Inc. shares may be available on secondary markets subject to transfer restrictions. Caplight facilitates secondary market transactions for accredited investors. Visit https://www.caplight.com to learn more.
When was ProCell Therapeutics, Inc.'s last funding round?
ProCell Therapeutics, Inc.'s most recent funding round was Series B on July 13, 2022.
Who are the main investors in ProCell Therapeutics, Inc.?
Key investors in ProCell Therapeutics, Inc. include Samsung Venture Investment, Korea Credit Guarantee Fund.
Will ProCell Therapeutics, Inc. IPO soon?
No public IPO plans have been announced for ProCell Therapeutics, Inc..
How can I track ProCell Therapeutics, Inc. secondary market activity?
Caplight tracks bids, offers, and trades for private companies. Visit https://www.caplight.com to monitor ProCell Therapeutics, Inc.'s secondary market activity and sign up for updates.